Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Pilot study of cell-free DNA (cfDNA) for measurable residual disease monitoring following autologous hematopoietic cell transplant in multiple myeloma

Yamuna Kondapally, Julie Fortier, Antony Tin, Sarah Kelley, Derrick Renner, Mark Fiala, Angel Rodriguez, Minetta Liu, Mark Schroeder, Keith Stockerl-Goldstein, Ravi Vij, Michael Slade

Blood (2025) 146 (Supplement 1): 2219.

https://doi.org/10.1182/blood-2025-2219

Published: 2025

Journal Articles

Real-world evaluation of ctdna for risk stratification across the spectrum of both aggressive and indolent lymphomas

Natalie Galanina, Madiha Iqbal, Darryl Nousome, Antony Tin, Cassandra Gillespie, Heather Youngberg, Shruti Sharma, J. Bryce Ortiz, Angel Rodriguez, Minetta Liu, Basem William

Blood (2025) 146 (Supplement 1): 281.

https://doi.org/10.1182/blood-2025-281

Published: 2025

Journal Articles

A novel method for molecular subtyping diffuse-large B-cell lymphoma using whole-exome sequencing

Daniel Kerr, Yuefan Huang, Antony Tin, Shruti Sharma, Sara Bristow, Angel Rodriguez, Minetta Liu

Blood (2025) 146 (Supplement 1): 4336.

https://doi.org/10.1182/blood-2025-4336

Published: 2025

Journal Articles

Whole-genome sequencing (WGS)-based circulating tumor DNA (ctDNA) monitoring in diffuse-large B-cell lymphoma (DLBCL)

Basem William, Madiha Iqbal, Natalie Galanina, Sarah Tomassetti, Cassandra Gillespie, Darryl Nousome, Antony Tin, Sharlene Velichko, Heather Youngberg, Catherine Bridges, Charuta Palsuledesai, Shruti Sharma, Angel Rodriguez, Minetta Liu, Mayur Narkhede

Blood (2025) 146 (Supplement 1): 4353.

https://doi.org/10.1182/blood-2025-4353

Published: 2025

Journal Articles

Circulating Tumor DNA As a Biomarker for Molecular Residual Disease Assessment in Patients with Diffuse Large B-Cell Lymphoma

Mayur Narkhede, Sarah Tomassetti, Madiha Iqbal, Katie LaBarbera, Hayley Widden, Ryan Benrud, Richa Rathore, Ekaterina Kalashnikova, Allyson Koyen Malashevich, Minetta Liu, Alexey Aleshin

Blood (2022) 140 (Supplement 1): 11884–11886.

https://doi.org/10.1182/blood-2022-169656

Published: 2022

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Pilot study of cell-free DNA (cfDNA) for measurable residual disease monitoring following autologous hematopoietic cell transplant in multiple myeloma

Real-world evaluation of ctdna for risk stratification across the spectrum of both aggressive and indolent lymphomas

A novel method for molecular subtyping diffuse-large B-cell lymphoma using whole-exome sequencing

Whole-genome sequencing (WGS)-based circulating tumor DNA (ctDNA) monitoring in diffuse-large B-cell lymphoma (DLBCL)

Circulating Tumor DNA As a Biomarker for Molecular Residual Disease Assessment in Patients with Diffuse Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Pilot study of cell-free DNA (cfDNA) for measurable residual disease monitoring following autologous hematopoietic cell transplant in multiple myeloma

Real-world evaluation of ctdna for risk stratification across the spectrum of both aggressive and indolent lymphomas

A novel method for molecular subtyping diffuse-large B-cell lymphoma using whole-exome sequencing

Whole-genome sequencing (WGS)-based circulating tumor DNA (ctDNA) monitoring in diffuse-large B-cell lymphoma (DLBCL)

Circulating Tumor DNA As a Biomarker for Molecular Residual Disease Assessment in Patients with Diffuse Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only